Search
Obiltoxaximab
go.drugbank.com/drugs/DB05336ApprovedObiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.
Phenformin
go.drugbank.com/drugs/DB00914ApprovedWithdrawnA biguanide hypoglycemic agent with actions and uses similar to those of metformin. … Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries.
Tenamfetamine
go.drugbank.com/drugs/DB01509IllicitInvestigationalIt is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Lycopene
go.drugbank.com/drugs/DB11231ApprovedLycopene is a naturally occurring red carotenoid pigment that is responsible for red to pink colors seen in tomatoes, pink grapefruit, and other foods [A27242].
Mixtures: Shine CO-Q PlusRUS 3108
go.drugbank.com/drugs/DB05911ExperimentalThe drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers. … RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
Sarafloxacin
go.drugbank.com/drugs/DB11491ApprovedVet approvedWithdrawnSarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Prostaglandin G2
go.drugbank.com/drugs/DB03866ExperimentalA cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]
Ulotaront
go.drugbank.com/drugs/DB15665InvestigationalUnlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5 … [A193506] SEP-363856 was developed by Sunovion pharmaceuticals.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.